Reviewed by Dr Sarah Mitchell, PhD · Editorial Board
Retatrutide UK status — patient view
Retatrutide is an investigational once-weekly triple-agonist drug from Eli Lilly. It is not approved in the UK, EU, US, or anywhere else. This page covers what's known so far, where the lawful UK access route is, and why the grey-market alternative is especially risky for an investigational drug with no licensed reference product.
What retatrutide is
Retatrutide (Eli Lilly code LY3437943) is a once-weekly peptide that activates three receptors simultaneously: GLP-1, GIP, and glucagon. The glucagon-receptor activation is the new element compared to tirzepatide (dual GLP-1 / GIP). Adding glucagon agonism increases energy expenditure as well as suppressing appetite.
The evidence so far
Phase 2 trial data (published in NEJM, 2023) reported mean weight loss around 24% at 48 weeks at the highest dose in adults with obesity — larger than the equivalent semaglutide and tirzepatide trial reports. Phase 3 trials are ongoing across obesity and type 2 diabetes indications.
Phase 3 will determine whether the phase 2 effect size holds at scale and what the safety profile looks like across a broader patient population.
Lawful UK access
The only lawful UK route to retatrutide is participation in a registered clinical trial.
- NIHR Be Part of Research — UK trial discovery portal.
- ClinicalTrials.gov — global registry; search for “retatrutide”.
- Specialist endocrinology / obesity centres in the UK have been recruiting for phase 3.
Why ‘research-grade retatrutide’ is especially risky
For licensed GLP-1 medicines (Wegovy, Mounjaro), a counterfeit can at least be compared to the genuine licensed product. For retatrutide, there is no licensed reference product anywhere in the world. That makes several risks worse:
- Identity unverifiable. Without a genuine consumer retatrutide product to compare against, there is no way to confirm a vial actually contains retatrutide.
- Concentration unverifiable. Independent testing of comparable unlicensed peptides has shown substantial vial-to-vial variability. Patients dosing from grey-market vials are dosing into an unknown.
- Safety profile under-characterised. Trial participants are monitored for cardiovascular, hepatic, and pancreatic effects. Consumers using grey-market product are not.
- Adverse-event reporting absent. An adverse event from a grey-market vial has no licensed-medicine framework to fall back on; the Yellow Card report can capture the AE but not address the supply chain that caused it.
What to do if you're considering retatrutide
- Talk to a GMC-registered prescriber about whether a currently licensed product (Wegovy / Mounjaro) fits your clinical picture.
- Search the NIHR Be Part of Research portal for active UK retatrutide trials.
- Avoid “research-grade retatrutide” from online suppliers — the grey-market risk profile is materially worse for an investigational drug.
Red-flag claims
If you see wording like this on a seller, clinic, or social-media advert, treat it as a warning sign rather than a benefit.
“Get retatrutide before it's licensed”
‘Before it's licensed’ is the wording of unlawful pre-market supply. No regulator has approved retatrutide; there is no licensed product to be ‘ahead of’.
“Pharma-grade retatrutide — Lilly research-batch product”
The Lilly clinical-trial supply chain is closed. ‘Lilly research batch’ on a research-chemical website is unverifiable and likely false.
“Compounded retatrutide — UK clinic prescribed”
The UK ‘specials’ framework requires evidence no licensed alternative is suitable. Licensed weight-management GLP-1s exist; substituting an investigational drug doesn't fit.
“Triple-agonist therapy — best results possible”
‘Best results’ from grey-market dosing of an investigational compound is marketing, not clinical evidence.
Sources & further reading
- NIHR — Be Part of Research — nihr.ac.uk
- ClinicalTrials.gov — clinicaltrials.gov
- MHRA — gov.uk
- Human Medicines Regulations 2012 — legislation.gov.uk